Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study

doi:10.1016/j.ijid.2020.12.023

科研成果详情

题名	Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study
作者	Li, Yuping1; Shi, Keqing1; Qi, Feng 2; Yu, Zhijie1; Chen, Chengshui1; Pan, Jingye1; Wu, Gaojun1; Chen, Yanfang 1; Li, Ji 1; Chen, Yongping1; Zhou, Tieli1; Li, Xiaokun1,3; Xia, Jinglin1,2
发表日期	2021-02
发表期刊	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Thalidomide Glucocorticoid COVID-19 Inflammatory cytokines Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
其他关键词	ACUTE KIDNEY INJURY ; CORONAVIRUS ; MANAGEMENT ; SUPPORT ; CELLS
摘要	Objectives: The aim was to evaluate the safety and effectiveness of thalidomide, an immunomodulatory agent, in combination with glucocorticoid, for the treatment of COVID-19 patients with life-threatening symptoms. Methods: A nonrandomized comparative case series study was performed. Six patients received thalidomide 100 mg per day (with therapy lasting for >= 7 days) plus low-dose short-term dexamethasone, and 6 control patients matched with patients in the thalidomide group, received low-dose short-term treatment with dexamethasone alone. The main outcomes were: the duration of SARS-CoV-2 negative conversion from admission; length of hospital stay; and changes in inflammatory cytokine concentrations and lymphocyte subsets. Results: The median thalidomide treatment time was 12.0 days. The median duration of SARS-CoV-2 negative conversion from admission and hospital stay length were briefer in the thalidomide group compared to the control group (respectively, 11.0 vs 23.0 days, P = 0.043; 18.5 vs 30.0 days, P = 0.043). The mean reduction rates at 7-10 days after treatment for serum interleukin-6 and interferon-gamma concentrations were greater in the thalidomide group compared to the control group. Alterations in lymphocyte numbers in the subsets between the 2 groups were similar. Conclusions: Thalidomide plus short-term glucocorticoid therapy is an effective and safe regimen for the treatment of severely ill COVID-19 patients. The mechanism of action is most likely inhibition of inflammatory cytokine production. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
出版者	ELSEVIER SCI LTD
出版地	OXFORD
ISSN	1201-9712
EISSN	1878-3511
卷号	103 页码:507-513
DOI	10.1016/j.ijid.2020.12.023
页数	7
WOS类目	Infectious Diseases
WOS研究方向	Infectious Diseases
WOS记录号	WOS:000616697100028
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	33333254
PMC记录号	PMC7834521
SCOPUSEID	2-s2.0-85098977856
通讯作者地址	[Xia, Jinglin]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China ; [Li, Xiaokun]International Collaborative Center on Growth Factor Research,and School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,325035,China
Scopus学科分类	Microbiology (medical);Infectious Diseases
引用统计	被引频次：11[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/3680
专题	附属第一医院药学院（分析测试中心）卓越中心_国际生长因子研究院
通讯作者	Li, Xiaokun; Xia, Jinglin
作者单位	1.The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China; 2.Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai,200032,China; 3.International Collaborative Center on Growth Factor Research,and School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,325035,China
第一作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
通讯作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院; 药学院（分析测试中心）
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Li, Yuping,Shi, Keqing,Qi, Feng,et al. Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study[J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES,2021,103:507-513.
APA	Li, Yuping., Shi, Keqing., Qi, Feng., Yu, Zhijie., Chen, Chengshui., ... & Xia, Jinglin. (2021). Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 103, 507-513.
MLA	Li, Yuping,et al."Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study".INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 103(2021):507-513.